GlassScriptPhysician profile
Dana R Hardesty
NPI 1962140756
$1,182.91
in general payments reported to CMS, 2019-2025
9 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $210 · 2024: $605 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.91 |
| Education | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $450.88 | 2024-2025 | Opdivo |
| Sobi, INC | $328.20 | 2024 | |
| Seagen INC. | $195.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $64.08 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $44.90 | 2024-2025 | Keytruda, Keytruda Qlex |
| Pharmacosmos Therapeutics INC. | $42.74 | 2025 | Monoferric |
| Abbvie INC. | $28.26 | 2025 | |
| Astellas Pharma Global Development | $15.18 | 2025 | Vyloy |
| Genzyme Corporation | $13.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.